VivoSeq
Other

Peripheral Blood Stem Cell Transplantation

0

Pipeline Programs↗

7

Active Trials↗

2

Companies Involved↗

Peripheral Blood Stem Cell Transplantation is an early-stage landscape with 0 programs across 2 companies. The most active players are Incyte, Tarix Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

69/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

0 programs

PreclinicalT

Tarix Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

22

clinical trials

Completed9 · 41%
Recruiting6 · 27%
Terminated2 · 9%
Withdrawn2 · 9%
Available1 · 5%
Active, not recruiting1 · 5%
Other1 · 5%

Clinical Trials

Trial Activity

22 trials

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Recruiting·HHannah Choe, MD·Phase 2·NCT07249346·124 enrolled
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Recruiting·Incyte logoIncyte·Phase 3·NCT06615050·572 enrolled
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT06398457·8 enrolled
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Recruiting·HHenry Ford Health System·Phase 2·NCT03850366·15 enrolled
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT05436418·260 enrolled
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Recruiting·CCenter for International Blood and Marrow Transplant Research·Phase 2·NCT06859424·358 enrolled
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Active, not recruiting·CCenter for International Blood and Marrow Transplant Research·Phase 2·NCT06001385·313 enrolled
Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
Completed·—·Phase 2·NCT02867384·181 enrolled
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01682226·84 enrolled
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation
Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT01634217·16 enrolled
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
Completed·WWashington University School of Medicine·Phase 1·NCT00314743·48 enrolled
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01525407·83 enrolled
Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation
Completed·—·Phase 2·NCT00282282·31 enrolled
Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00504634·8 enrolled
Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor
Completed·KKing Faisal Specialist Hospital & Research Center·N/A·NCT00531583·350 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)